FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313704005> ?p ?o ?g. }

• W4313704005 abstract "Abstract Purpose Despite the poor prognosis of triple-negative breast cancer (TNBC), it has been demonstrated that neoadjuvant immunotherapy in combination with chemotherapy can improve the pathologic complete response (pCR) rate and/or long-term outcome of TNBC. However, there have been no real-world studies reporting on the effectiveness of neoadjuvant checkpoint inhibitors in early TNBC. Methods Between November 2019 and December 2021, 63 early TNBC patients treated with anti-PD-1 antibodies (pembrolizumab or camrelizumab) or anti-PD-L1 antibody (atezolizumab) in combination with chemotherapy at seven institutions were included. PCR1 defined as ypT0/Tis and ypN0 was the primary endpoint. Secondary endpoints included pCR2 defined as ypT0/Tis, overall response rate (ORR), disease-free survival (DFS), drug-related adverse events (AEs) and biomarkers. Results Among the patients in the current study, 34.9% of patients were able to achieve pCR1, and 47.6% of patients had achieved pCR2. The ORR was 82.5%. 33 patients with non-pCR2 tumors were found to have a median DFS of 20.7 months (95% CI 16.3 months-not reached). The DFS of patients with pCR2 and non-pCR2 after neoadjuvant therapy was significantly different (HR = 0.28, 95% CI 0.10–0.79; P = 0.038). The most common AEs were nausea (63.4%), fatigue (42.7%), leucopenia (30.0%) and elevated transaminase (11.7%). Conclusion It is possible to achieve a meaningful pCR rate and DFS by combining neoadjuvant checkpoint blockade with chemotherapy in patients with high-risk TNBC. Compared to clinical trials, however, there was a slightly lower pCR rate in this multicentered real-world study." @default.
• W4313704005 created "2023-01-08" @default.
• W4313704005 creator A5046338175 @default.
• W4313704005 creator A5050745363 @default.
• W4313704005 creator A5054199475 @default.
• W4313704005 creator A5054459491 @default.
• W4313704005 creator A5055751859 @default.
• W4313704005 creator A5059430503 @default.
• W4313704005 creator A5069202094 @default.
• W4313704005 creator A5083771255 @default.
• W4313704005 creator A5084947802 @default.
• W4313704005 creator A5090728786 @default.
• W4313704005 date "2023-01-07" @default.
• W4313704005 modified "2023-10-18" @default.
• W4313704005 title "Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data" @default.
• W4313704005 cites W1994993231 @default.
• W4313704005 cites W2083296039 @default.
• W4313704005 cites W2207850678 @default.
• W4313704005 cites W2618058692 @default.
• W4313704005 cites W2744067212 @default.
• W4313704005 cites W2762554941 @default.
• W4313704005 cites W2767395146 @default.
• W4313704005 cites W2775269156 @default.
• W4313704005 cites W2793180707 @default.
• W4313704005 cites W2897422388 @default.
• W4313704005 cites W2946550606 @default.
• W4313704005 cites W3005738019 @default.
• W4313704005 cites W3006930853 @default.
• W4313704005 cites W3008792561 @default.
• W4313704005 cites W3027227763 @default.
• W4313704005 cites W3036334626 @default.
• W4313704005 cites W3086437055 @default.
• W4313704005 cites W3087393791 @default.
• W4313704005 cites W3097803258 @default.
• W4313704005 cites W3109853980 @default.
• W4313704005 cites W3134731856 @default.
• W4313704005 cites W3164523869 @default.
• W4313704005 cites W3173705400 @default.
• W4313704005 cites W3183916035 @default.
• W4313704005 cites W4213010786 @default.
• W4313704005 cites W4229079181 @default.
• W4313704005 cites W4241868283 @default.
• W4313704005 doi "https://doi.org/10.1186/s12885-023-10515-z" @default.
• W4313704005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36611131" @default.
• W4313704005 hasPublicationYear "2023" @default.
• W4313704005 type Work @default.
• W4313704005 citedByCount "1" @default.
• W4313704005 countsByYear W43137040052023 @default.
• W4313704005 crossrefType "journal-article" @default.
• W4313704005 hasAuthorship W4313704005A5046338175 @default.
• W4313704005 hasAuthorship W4313704005A5050745363 @default.
• W4313704005 hasAuthorship W4313704005A5054199475 @default.
• W4313704005 hasAuthorship W4313704005A5054459491 @default.
• W4313704005 hasAuthorship W4313704005A5055751859 @default.
• W4313704005 hasAuthorship W4313704005A5059430503 @default.
• W4313704005 hasAuthorship W4313704005A5069202094 @default.
• W4313704005 hasAuthorship W4313704005A5083771255 @default.
• W4313704005 hasAuthorship W4313704005A5084947802 @default.
• W4313704005 hasAuthorship W4313704005A5090728786 @default.
• W4313704005 hasBestOaLocation W43137040051 @default.
• W4313704005 hasConcept C121608353 @default.
• W4313704005 hasConcept C126322002 @default.
• W4313704005 hasConcept C143998085 @default.
• W4313704005 hasConcept C170493617 @default.
• W4313704005 hasConcept C197934379 @default.
• W4313704005 hasConcept C2775949291 @default.
• W4313704005 hasConcept C2776694085 @default.
• W4313704005 hasConcept C2777701055 @default.
• W4313704005 hasConcept C2778468042 @default.
• W4313704005 hasConcept C2780057760 @default.
• W4313704005 hasConcept C2780110267 @default.
• W4313704005 hasConcept C2780580376 @default.
• W4313704005 hasConcept C530470458 @default.
• W4313704005 hasConcept C71924100 @default.
• W4313704005 hasConceptScore W4313704005C121608353 @default.
• W4313704005 hasConceptScore W4313704005C126322002 @default.
• W4313704005 hasConceptScore W4313704005C143998085 @default.
• W4313704005 hasConceptScore W4313704005C170493617 @default.
• W4313704005 hasConceptScore W4313704005C197934379 @default.
• W4313704005 hasConceptScore W4313704005C2775949291 @default.
• W4313704005 hasConceptScore W4313704005C2776694085 @default.
• W4313704005 hasConceptScore W4313704005C2777701055 @default.
• W4313704005 hasConceptScore W4313704005C2778468042 @default.
• W4313704005 hasConceptScore W4313704005C2780057760 @default.
• W4313704005 hasConceptScore W4313704005C2780110267 @default.
• W4313704005 hasConceptScore W4313704005C2780580376 @default.
• W4313704005 hasConceptScore W4313704005C530470458 @default.
• W4313704005 hasConceptScore W4313704005C71924100 @default.
• W4313704005 hasFunder F4320321921 @default.
• W4313704005 hasIssue "1" @default.
• W4313704005 hasLocation W43137040051 @default.
• W4313704005 hasLocation W43137040052 @default.
• W4313704005 hasLocation W43137040053 @default.
• W4313704005 hasLocation W43137040054 @default.
• W4313704005 hasOpenAccess W4313704005 @default.
• W4313704005 hasPrimaryLocation W43137040051 @default.
• W4313704005 hasRelatedWork W2534174115 @default.
• W4313704005 hasRelatedWork W2948845624 @default.
• W4313704005 hasRelatedWork W3010740851 @default.
• W4313704005 hasRelatedWork W3113081998 @default.

• next